711 results on '"von Mehren, Margaret"'
Search Results
52. Supplementary Figures 1 - 3 from Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
53. Data from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
54. Supplementary Figure 2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
55. Supplementary Tables 1-5 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
56. Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
57. Supplementary Figure Legends 1-2 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
58. Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.
59. Additional file 1 of Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
60. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
61. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments
62. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
63. Gastrointestinal Stromal Tumors
64. Soft Tissue Sarcoma, Version 2.2022
65. Dataset for reporting of gastrointestinal stromal tumours: recommendations from the International Collaboration on Cancer Reporting ( ICCR )
66. OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma
67. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor
68. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies
69. Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence
70. Pan-sarcoma analysis of DNA damage response pathway alterations and deficiency.
71. DNA damage response pathways in synovial sarcoma.
72. Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.
73. Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST).
74. Age as a factor in the molecular landscape and the tumor-microenvironmental signature of osteosarcoma.
75. Using pan-sarcoma multiomic analysis for identifying sarcoma subtypes with immunogenic potential.
76. Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.
77. Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
78. INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
79. Insulin-Like Growth Factor 1 Receptor Is a Potential Therapeutic Target for Gastrointestinal Stromal Tumors
80. Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
81. GIST Treatment Options after Tyrosine Kinase Inhibitors
82. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
83. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
84. Dataset for reporting of gastrointestinal stromal tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR).
85. ASO Visual Abstract: National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma—A Modern Appraisal of Variability in Therapeutic Strategies
86. National Trends in Treatment for Retroperitoneal Soft Tissue Sarcoma: A Modern Appraisal of Variability in Therapeutic Strategies
87. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
88. 33 - Gastrointestinal Stromal Tumors
89. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
90. Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis
91. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
92. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
93. Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor
94. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
95. Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies
96. Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132
97. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
98. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
99. SMARCA2‐NR4A3is a novel fusion gene of extraskeletal myxoid chondrosarcoma identified by RNA next‐generation sequencing
100. Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.